Progenity Overview

  • Founded
  • 2010
Founded
  • Status
  • Public
  • Employees
  • 637
Employees
  • Stock Symbol
  • PROG
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $2.21
  • (As of Thursday Closing)

Progenity General Information

Description

Progenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products as well as innovating in the field of precision medicine. It utilizes a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to molecular testing products and to the development of a suite of investigational ingestible devices and drug and device combinations designed to provide precise diagnostic sampling and drug delivery solutions. The firm generates its revenue from molecular laboratory tests, principally from the sale of Innatal, Preparent, and pathology molecular testing. The company's operations are carried out in the United States.

Contact Information

Formerly Known As
Ascendant MDX
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 4330 La Jolla Village Drive
  • Suite 200
  • San Diego, CA 92122
  • United States
+1 (855) 000-0000

Progenity Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Progenity Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.21 $2.45 $2.04 - $10.27 $190M 77.4M 2.24M -$9.21

Progenity Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 357,033 309,516
Revenue 82,011 74,313 143,985 127,974
EBITDA (185,060) (190,129) (135,440) (110,493)
Net Income (207,640) (192,528) (148,037) (129,106)
Total Assets 128,577 154,440 101,727 116,397
Total Debt 162,445 162,310 73,373 72,737
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Progenity Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Progenity‘s full profile, request access.

Request a free trial

Progenity Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Progenity‘s full profile, request access.

Request a free trial

Progenity Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Progenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products as
Laboratory Services (Healthcare)
San Diego, CA
637 As of 2021
00000
000000000 00000

00000000

n voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000000000000
Shatin, Hong Kong
0 As of 0000
00000000000

000000

empor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitatio
0000000000 00000000 (0000000000)
Gaithersburg, MD
000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Progenity Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vitargent (International) Biotechnology Venture Capital-Backed Shatin, Hong Kong 0 00000000000
000000 Corporate Backed or Acquired Gaithersburg, MD 000000&0
00000 00000000 Private Equity-Backed Aliso Viejo, CA 000 000000&0
000000 Formerly VC-backed Hilden, Germany 0000 00000 000000&0
00000000 Private Equity-Backed Paterna, Spain 000 000000&0
You’re viewing 5 of 12 competitors. Get the full list »

Progenity Executive Team (29)

Name Title Board Seat Contact Info
Harry Stylli Ph.D Chief Executive Officer & Chairman
Eric d'Esparbes Chief Financial Officer
Damon Silvestry Chief Operating Officer, Operations
Hutan Hashemi Chief Compliance Officer, Legal
Troy Seelye Chief Information Officer
You’re viewing 5 of 29 executive team members. Get the full list »

Progenity Board Members (12)

Name Representing Role Since
Brian Kotzin Self Board Member 000 0000
Brian Kotzin Progenity Board Member 000 0000
Harry Stylli Ph.D Progenity Chief Executive Officer & Chairman 000 0000
Jeffrey Alter Self Board Member 000 0000
Jeffrey Ferrell Athyrium Capital Management Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Progenity Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Progenity Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Progenity‘s full profile, request access.

Request a free trial

Progenity Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 (00000 18-Sep-2019 000000000 00000 00 Buildings and Property 00000 000000 00.0
00000000 000000000 01-Jun-2015 000000000 00000 00 Buildings and Property
Carmenta Bioscience 29-Apr-2015 Merger/Acquisition Biotechnology 00000 000000 00.0
To view Progenity’s complete investments and acquisitions history, request access »

Progenity Subsidiaries (1)

Company Name Industry Location Founded
00000000 000000000 Biotechnology Palo Alto, CA 0000
To view Progenity’s complete subsidiaries history, request access »